DNA Double Strand Break Repair - Related Synthetic Lethality.
作者： Monika Toma , Tomasz Skorski , Tomasz Sliwinski
DOI: 10.2174/0929867325666180201114306
关键词:
摘要: Cancer is a heterogeneous disease with high degree of diversity between and within tumors. Our limited knowledge their biology results in ineffective treatment. However, personalized approach may represent milestone the field anticancer therapy. It can increase specificity treatment against tumor initiating cancer stem cells (CSCs) progenitor (CPCs) minimal effect on normal tissues. Cancerous carry multiple genetic epigenetic aberrations which disrupt pathways essential for cell survival. Discovery synthetic lethality has led new hope creating effective antitumor Synthetic occurs when simultaneous inactivation two genes or products causes death whereas individual either gene not lethal. The effectiveness numerous anti-tumor therapies depends induction DNA damage therefore expressing abnormalities whose are crucial repair promising targets lethality. Here, we discuss mechanistic aspects context deficiencies double strand break pathways. In addition, review clinical trials utilizing interactions mechanisms resistance.
eurekaselect.com参考文章(326)
Fiona M. Frame, Norman J. Maitland, Cancer stem cells, models of study and implications of therapy resistance mechanisms. Advances in Experimental Medicine and Biology. ,vol. 720, pp. 105- 118 ,(2011) , 10.1007/978-1-4614-0254-1_9
Katheryn Meek, Van Dang, Susan P. Lees-Miller, Chapter 2 DNA-PK Elsevier. pp. 33- 58 ,(2008) , 10.1016/S0065-2776(08)00602-0
Susan P. Lees-Miller, Van Dang, Katheryn Meek, DNA-PK: the means to justify the ends? Advances in Immunology. ,vol. 99, pp. 33- 58 ,(2008) , 10.1016/S0065-2776(08)00602-0
Rebecca Sophie Kristeleit, Howard A. Burris, Patricia LoRusso, Manish R. Patel, Uzma Saddia Asghar, Fatima El-Khouly, Alan Hilary Calvert, Jeffrey R. Infante, John Frederick Hilton, Sara M. Tolaney, Muaiad Kittaneh, Heidi Giordano, Jennifer Borrow, Sarah S. Jaw-Tsai, Geoffrey Shapiro, Phase 1/2 study of oral rucaparib: Final phase 1 results. Journal of Clinical Oncology. ,vol. 32, pp. 2573- 2573 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.2573
Jing Huang, Lei Wang, Zhongyi Cong, Zohreh Amoozgar, Evgeny Kiner, Deyin Xing, Sandra Orsulic, Ursula Matulonis, Michael S. Goldberg, The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochemical and Biophysical Research Communications. ,vol. 463, pp. 551- 556 ,(2015) , 10.1016/J.BBRC.2015.05.083
George Iliakis, Tamara Murmann, Aashish Soni, Alternative end-joining repair pathways are the ultimate backup for abrogated classical non-homologous end-joining and homologous recombination repair: Implications for the formation of chromosome translocations. Mutation Research-genetic Toxicology and Environmental Mutagenesis. ,vol. 793, pp. 166- 175 ,(2015) , 10.1016/J.MRGENTOX.2015.07.001
Zhiyong Mao, Ying Jiang, Xiang Liu, Andrei Seluanov, Vera Gorbunova, DNA Repair by Homologous Recombination, But Not by Nonhomologous End Joining, Is Elevated in Breast Cancer Cells Neoplasia. ,vol. 11, pp. 683- 691 ,(2009) , 10.1593/NEO.09312
M.S. Satoh, G.G. Poirier, T. Lindahl, NAD(+)-dependent repair of damaged DNA by human cell extracts. Journal of Biological Chemistry. ,vol. 268, pp. 5480- 5487 ,(1993) , 10.1016/S0021-9258(18)53346-9
Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E. Garber, Christina Herold, Leif Ellisen, Jill Krejdovsky, Kim DeLeonardis, Kristin Sedgwick, Kathleen Soltis, Benjamin Roa, Richard J. Wenstrup, Anne-Renee Hartman, Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel Cancer. ,vol. 121, pp. 25- 33 ,(2015) , 10.1002/CNCR.29010